Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by PoorOpinionon Jun 06, 2018 9:57am

182 Views

Post# 28131358

Questions for Mengkung

Was the discussion at the agm mainly about Trogarzo?

Did they say anything about the IM version, the timetable for the rest of their pipeline?

Did they say anything about their long term vision of becoming a fully intergrated pharma? Did they discuss things beyond their immediate pipeline?

I'd be interested to hear anything else.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?